Partnering

VIA is looking to expand its portfolio of products and development projects through in-licensing, acquisition and co-development collaborations. We are open to partnering with companies on the development of our products that provide therapeutic benefits to patients in the areas of inflammatory and cardiovascular diseases.

With a pipeline of pre-clinical and clinical-stage small-molecule drugs that intervene directly with selected molecular targets in the inflammatory process, the VIA team provides our partners with accomplished leadership and development expertise capabilities. By focusing on key therapeutic areas of inflammation and cardiovascular disease, VIA is able to offer a unique collaborative approach for its partners to both develop and commercialize novel, high-value therapeutics that solve unmet medical needs.

If you are interested in discussing potential partnering opportunities with the VIA team, please contact us directly:

Brendan Rae, Ph.D, JD
Vice President, Business Development
Tel: 415-702-7454
E-mail: brendan.rae@viapharmaceuticals.com

Jun Yoon
Director, Business Development
Tel: 415-283-2207
E-mail: jun.yoon@viapharmaceuticals.com

Click here for more informating regarding our lead candidate, VIA-2291

via 2291 broad development plan

Product Pipeline

Our pipeline includes pre-clinical and clinical-stage small-molecule drugs that intervene directly with selected molecular targets in the inflammatory process

VIA-2291

Potentially a complement to current standard of care therapies that treat risk factors, such as statins, antiplatelet and blood pressure medications, VIA-2291 is initially targeted to address the secondary prevention market for patients who have already suffered a major adverse cardiac event.